Orchestra BioMed (OBIO) News Today $2.74 -0.21 (-7.12%) Closing price 04:00 PM EasternExtended Trading$2.74 +0.00 (+0.18%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OBIO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period What is Chardan Capital's Forecast for OBIO FY2026 Earnings?May 18 at 3:19 AM | americanbankingnews.comOrchestra BioMed (NASDAQ:OBIO) Announces Quarterly Earnings ResultsOrchestra BioMed (NASDAQ:OBIO - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.03). Orchestra BioMed had a negative net margin of 2,179.33% and a negative return on equity of 107.04%.May 14, 2025 | marketbeat.comOrchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative OptimismMay 14, 2025 | seekingalpha.comOrchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical MilestonesMay 12, 2025 | globenewswire.comOrchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough DesignationMay 11, 2025 | msn.comOrchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global PatentsMay 9, 2025 | nasdaq.comOrchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureMay 8, 2025 | finance.yahoo.comBarclays Has Lowered Expectations for Orchestra BioMed (NASDAQ:OBIO) Stock PriceBarclays dropped their target price on Orchestra BioMed from $16.00 to $12.00 and set an "overweight" rating for the company in a research report on Monday.May 7, 2025 | marketbeat.comOrchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureMay 7, 2025 | globenewswire.comBoxer Capital Management LLC Makes New $953,000 Investment in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO)Boxer Capital Management LLC acquired a new position in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 238,193 shares of the company's stock, valued at approximately $May 4, 2025 | marketbeat.comOrchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR TreatmentMay 1, 2025 | msn.comOrchestra BioMed to Present at Jefferies Global Healthcare ConferenceMay 1, 2025 | msn.comFDA approves head-to-head trial of Orchestra BioMed’s balloonApril 30, 2025 | investing.comOrchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% - Time to Sell?Orchestra BioMed (NASDAQ:OBIO) Trading Down 6.1% - Should You Sell?April 30, 2025 | marketbeat.comOrchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated BalloonApril 29, 2025 | globenewswire.comOrchestra BioMed to Participate in Upcoming Institutional Investor ConferencesApril 28, 2025 | globenewswire.comOrchestra BioMed (NASDAQ:OBIO) Given Buy Rating at Chardan CapitalChardan Capital reiterated a "buy" rating and set a $20.00 price target on shares of Orchestra BioMed in a research report on Tuesday.April 24, 2025 | marketbeat.comOrchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025April 24, 2025 | msn.comOrchestra BioMed announces AVIM therapy-focused satellite symposium at HRS 2025April 23, 2025 | markets.businessinsider.comOrchestra BioMed granted breakthrough device designation, says H.C. WainwrightApril 23, 2025 | markets.businessinsider.comOrchestra BioMed Secures FDA Breakthrough Device Designation for AVIM TherapyApril 23, 2025 | msn.comOrchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual MeetingApril 23, 2025 | globenewswire.comOrchestra BioMed shares surge on FDA breakthrough designationApril 22, 2025 | in.investing.comOrchestra BioMed Receives FDA Breakthrough Device Designation for AVIM TherapyApril 22, 2025 | globenewswire.comWhat is B. Riley's Estimate for OBIO Q1 Earnings?Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Equities researchers at B. Riley issued their Q1 2026 earnings per share estimates for shares of Orchestra BioMed in a research note issued to investors on Thursday, April 3rd. B. Riley analyst A. Schock expects that the company will pApril 8, 2025 | marketbeat.comChardan Capital Has Strong Outlook for OBIO FY2025 EarningsOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Investment analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for shares of Orchestra BioMed in a research note issued on Wednesday, April 2nd. Chardan Capital analyst K. Nakae now forecasts that the comApril 8, 2025 | marketbeat.comOrchestra BioMed (NASDAQ:OBIO) Upgraded by B. Riley to "Strong-Buy" RatingB. Riley raised shares of Orchestra BioMed to a "strong-buy" rating in a research note on Thursday.April 7, 2025 | marketbeat.comOrchestra BioMed (NASDAQ:OBIO) Given New $12.00 Price Target at HC WainwrightHC Wainwright dropped their price target on shares of Orchestra BioMed from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Friday.April 6, 2025 | marketbeat.comOrchestra BioMed price target lowered to $12 from $14 at H.C. WainwrightApril 5, 2025 | markets.businessinsider.com4OBIO : Where Orchestra BioMed Hldgs Stands With AnalystsApril 4, 2025 | benzinga.comOrchestra BioMed's (OBIO) Buy Rating Reiterated at Chardan CapitalChardan Capital reissued a "buy" rating and set a $20.00 price target on shares of Orchestra BioMed in a report on Tuesday.April 4, 2025 | marketbeat.comOrchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular TherapyApril 2, 2025 | msn.comOrchestra BioMed (NASDAQ:OBIO) Posts Earnings Results, Hits EstimatesOrchestra BioMed (NASDAQ:OBIO - Get Free Report) released its earnings results on Monday. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). Orchestra BioMed had a negative net margin of 2,179.33% and a negative return on equity of 107.04%.April 1, 2025 | marketbeat.comOrchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business UpdateMarch 31, 2025 | globenewswire.comOrchestra BioMed initiated with a Buy at BTIGMarch 21, 2025 | markets.businessinsider.comBTIG Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy RecommendationMarch 21, 2025 | msn.comOrchestra BioMed (NASDAQ:OBIO) Coverage Initiated at BTIG ResearchBTIG Research began coverage on Orchestra BioMed in a report on Thursday. They issued a "buy" rating and a $12.00 price objective on the stock.March 21, 2025 | marketbeat.comOrchestra BioMed (OBIO) Projected to Post Earnings on WednesdayOrchestra BioMed (NASDAQ:OBIO) will be releasing earnings before the market opens on Wednesday, March 26, Financial Modeling Prep reports.March 19, 2025 | marketbeat.comOrchestra BioMed's (OBIO) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $14.00 target price on shares of Orchestra BioMed in a research note on Monday.March 10, 2025 | marketbeat.comOrchestra BioMed (NASDAQ:OBIO) Stock Price Up 3.4% - Still a Buy?Orchestra BioMed (NASDAQ:OBIO) Stock Price Up 3.4% - Here's What HappenedMarch 8, 2025 | marketbeat.comOrchestra BioMed to Present at Upcoming Investor ConferencesFebruary 20, 2025 | globenewswire.comOrchestra names Vivek Reddy as chairman of BACKBEAT study steering committeeFebruary 19, 2025 | markets.businessinsider.comOrchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory BoardFebruary 18, 2025 | globenewswire.comBarclays Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)February 15, 2025 | markets.businessinsider.comOrchestra BioMed (NASDAQ:OBIO) Trading 5.1% Higher - Here's WhyOrchestra BioMed (NASDAQ:OBIO) Trading Up 5.1% - What's Next?February 14, 2025 | marketbeat.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Sees Large Decline in Short InterestOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 474,000 shares, a decline of 35.7% from the January 15th total of 736,700 shares. Based on an average daily volume of 97,000 shares, the short-interest ratio is presently 4.9 days. Approximately 1.8% of the company's shares are short sold.February 14, 2025 | marketbeat.comOrchestra BioMed announces data on atrioventricular interval modulation therapyFebruary 12, 2025 | markets.businessinsider.comOrchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 ConferenceFebruary 12, 2025 | globenewswire.comOrchestra BioMed announces appointment of Cleary to board of directorsFebruary 6, 2025 | markets.businessinsider.comOrchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of DirectorsFebruary 5, 2025 | globenewswire.com Get Orchestra BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address OBIO Media Mentions By Week OBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OBIO News Sentiment▼0.500.66▲Average Medical News Sentiment OBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OBIO Articles This Week▼51▲OBIO Articles Average Week Get Orchestra BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TMCI News Today CLPT News Today NNOX News Today STIM News Today SMTI News Today ZIMV News Today TCMD News Today NYXH News Today NVRO News Today DRTS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OBIO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OBIO Stock Free OBIO Stock Alerts